417 related articles for article (PubMed ID: 15379937)
1. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
[TBL] [Abstract][Full Text] [Related]
2. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.
Quella SK; Loprinzi CL; Sloan J; Novotny P; Perez EA; Burch PA; Antolak SJ; Pisansky TM
J Urol; 1999 Jul; 162(1):98-102. PubMed ID: 10379749
[TBL] [Abstract][Full Text] [Related]
3. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
4. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
Ulloa EW; Salup R; Patterson SG; Jacobsen PB
Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
[TBL] [Abstract][Full Text] [Related]
5. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
Gomella LG
BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
[TBL] [Abstract][Full Text] [Related]
6. Circadian rhythm of hot flashes and activity levels among prostate cancer patients on androgen deprivation therapy.
Hanisch LJ; Gehrman PR
Aging Male; 2011 Dec; 14(4):243-8. PubMed ID: 21627561
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy and safety of Salvia officinalis in controlling hot flashes in prostate cancer patients treated with androgen deprivation.
Vandecasteele K; Ost P; Oosterlinck W; Fonteyne V; Neve WD; Meerleer GD
Phytother Res; 2012 Feb; 26(2):208-13. PubMed ID: 21630361
[TBL] [Abstract][Full Text] [Related]
8. Managing hot flashes in men being treated for prostate cancer.
Baum NH; Torti DC
Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
[TBL] [Abstract][Full Text] [Related]
9. Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer.
Langenstroer P; Kramer B; Cutting B; Amling C; Poultan T; Lance R; Thrasher JB
J Urol; 2005 Aug; 174(2):642-5. PubMed ID: 16006929
[TBL] [Abstract][Full Text] [Related]
10. Hot flashes in prostate cancer: state of the science.
Engstrom CA
Am J Mens Health; 2008 Jun; 2(2):122-32. PubMed ID: 19477776
[TBL] [Abstract][Full Text] [Related]
11. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
[TBL] [Abstract][Full Text] [Related]
12. Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison.
Gonzalez BD; Jim HS; Donovan KA; Small BJ; Sutton SK; Park J; Lin HY; Spiess PE; Fishman MN; Jacobsen PB
J Urol; 2015 Sep; 194(3):690-5. PubMed ID: 25791402
[TBL] [Abstract][Full Text] [Related]
13. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
Miller NL; Bissonette EA; Bahnson R; Wilson J; Theodorescu D
Cancer; 2003 Mar; 97(5):1203-10. PubMed ID: 12599226
[TBL] [Abstract][Full Text] [Related]
14. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
Joly F; Alibhai SM; Galica J; Park A; Yi QL; Wagner L; Tannock IF
J Urol; 2006 Dec; 176(6 Pt 1):2443-7. PubMed ID: 17085125
[TBL] [Abstract][Full Text] [Related]
15. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
16. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E;
J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
Freedland SJ; Eastham J; Shore N
Prostate Cancer Prostatic Dis; 2009; 12(4):333-8. PubMed ID: 19901933
[TBL] [Abstract][Full Text] [Related]
19. Managing complications of androgen deprivation therapy for prostate cancer.
Holzbeierlein JM
Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
[TBL] [Abstract][Full Text] [Related]
20. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
Segal RJ; Reid RD; Courneya KS; Malone SC; Parliament MB; Scott CG; Venner PM; Quinney HA; Jones LW; D'Angelo ME; Wells GA
J Clin Oncol; 2003 May; 21(9):1653-9. PubMed ID: 12721238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
